IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid

Shots: The companies have expanded their clinical trial collaboration and supply agreement for IDE196 and crizotinib. The study will evaluate combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including MUM, skin melanoma, lung cancer, and colorectal cancer The two global companies have established JDC and there will be joint decision […]Read More

GSK Signs a Synthetic Lethality Cancer Agreement with Ideaya for

Shots: Ideaya to receive ~$100M as upfront in cash, $20M as equity investment, $50M in cash as option exercise fee for the MAT2A program and is eligible to receive preclinical, clinical, and commercial milestones The collaboration includes Ideaya’s synthetic lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials […]Read More

PharmaShots Weekly Snapshot (March 16-20, 2020)

1. Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform Published: Mar 19, 2020 | Tags: Merck, Collaborates, Dragonfly, Develop, Commercialize, Novel Therapies, Utilizing, TriNKET Platform 2.  BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US Published: Mar 20, 2020 | Tags: BGI, Reports, Availability, RT-PCR, SARS-CoV-2 […]Read More

IDEAYA and Pfizer Collaborate to Evaluate IDE196 + Binimetinib in

Shots: The companies entered into a clinical trial collaboration and supply agreement to evaluate the combination of IDE196 + binimetinib for GNAQ or GNA11 hotspot mutated solid tumors, including MUM, CM & CRC. The study is expected to be initiated in mid-2020 The clinical study will assess whether inhibition of the MAP-Kinase pathway at two […]Read More